4.7 Article

Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 70, Issue 6, Pages 766-775

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.06.012

Keywords

biocompatible materials; heart failure; myocardial infarction; myocardium; stem cells

Funding

  1. National Institutes of Health (NIH) [NIH UO1 HL134764]
  2. Progenitor Cell Biology Consortium [rant HL099997]
  3. Korea Health Promotion Institute [HI16C2211010017] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Transplantations of various stem cells or their progeny have repeatedly improved cardiac performance in animal models of myocardial injury; however, the benefits observed in clinical trials have been generally less consistent. Some of the recognized challenges are poor engraftment of implanted cells and, in the case of human cardiomyocytes, functional immaturity and lack of electrical integration, leading to limited contribution to the heart's contractile activity and increased arrhythmogenic risks. Advances in tissue and genetic engineering techniques are expected to improve the survival and integration of transplanted cells, and to support structural, functional, and bioenergetic recovery of the recipient hearts. Specifically, application of a prefabricated cardiac tissue patch to prevent dilation and to improve pumping efficiency of the infarcted heart offers a promising strategy for making stem cell therapy a clinical reality. (C) 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available